QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:IVVD

Invivyd (IVVD) Stock Price, News & Analysis

$4.04
+0.05 (+1.25%)
(As of 02/22/2024 ET)
Today's Range
$3.89
$4.14
50-Day Range
$1.63
$5.04
52-Week Range
$0.98
$5.20
Volume
330,034 shs
Average Volume
882,730 shs
Market Capitalization
$444.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Invivyd MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
135.1% Upside
$9.50 Price Target
Short Interest
Healthy
4.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$19.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

438th out of 934 stocks

Biological Products, Except Diagnostic Industry

67th out of 159 stocks


IVVD stock logo

About Invivyd Stock (NASDAQ:IVVD)

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Stock Price History

IVVD Stock News Headlines

Invivyd (NASDAQ:IVVD) Trading Down 2.7%
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Invivyd Refiles Financials Citing Viability Concerns
When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move
He started from nothing and became a multimillionaire...He's now one of the most sought-after trading experts...Yet he operates 858 miles from Wall Street.And now, he's revealing his #1 favorite strategy that targets MASSIVE weekly profits with just one stock ticker.
Invivyd just upgraded at Morgan Stanley, here's why
Invivyd, Inc. (IVVD)
Invivyd Inc Ordinary Shares IVVD
Invivyd to Participate in Upcoming Investor Conferences
See More Headlines
Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/22/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+130.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-241,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.27 per share

Miscellaneous

Free Float
89,083,000
Market Cap
$453.65 million
Optionable
Optionable
Beta
0.74
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 48)
    CEO & Director
    Comp: $932.5k
  • Ms. Jill Andersen J.D. (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $619.33k
  • Mr. William E. Duke Jr. (Age 52)
    M.B.A., Chief Financial Officer
  • Mr. Jeremy Gowler (Age 47)
    Chief Operating Officer & Chief Commercial Officer
  • Ms. Stacy Price M.S. (Age 55)
    Chief Technology & Manufacturing Officer
  • Dr. Robert D. Allen Ph.D.
    Chief Scientific Officer
  • Ms. Julie Green M.B.A.
    Senior Vice President of Human Resources
  • Dr. Peter C. Schmidt M.D. (Age 43)
    M.S., M.Sc., Chief Medical Officer
  • Ms. Heidi Spurling M.S.
    VP of Strategy & Operations and Chief of Staff to the CEO














IVVD Stock Analysis - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IVVD shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price target for 2024?

2 brokers have issued 12-month price objectives for Invivyd's shares. Their IVVD share price targets range from $4.00 to $15.00. On average, they anticipate the company's share price to reach $9.50 in the next year. This suggests a possible upside of 135.1% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2024?

Invivyd's stock was trading at $3.94 at the beginning of the year. Since then, IVVD shares have increased by 2.5% and is now trading at $4.04.
View the best growth stocks for 2024 here
.

Are investors shorting Invivyd?

Invivyd saw a decline in short interest in January. As of January 31st, there was short interest totaling 1,990,000 shares, a decline of 26.6% from the January 15th total of 2,710,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is currently 1.2 days. Currently, 4.4% of the company's shares are short sold.
View Invivyd's Short Interest
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our IVVD earnings forecast
.

What ETF holds Invivyd's stock ?

Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

Who are Invivyd's major shareholders?

Invivyd's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.28%), Bridgeway Capital Management LLC (0.46%), Charles Schwab Investment Management Inc. (0.28%), Balyasny Asset Management L.P. (0.08%), a16z Perennial Management L.P. (0.07%) and Barclays PLC (0.07%).
View institutional ownership trends
.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVVD) was last updated on 2/22/2024 by MarketBeat.com Staff